Kathryn Romano - 26 Feb 2024 Form 4 Insider Report for Krystal Biotech, Inc. (KRYS)

Role
Chief Accounting Officer
Signature
/s/ Kathryn Romano
Issuer symbol
KRYS
Transactions as of
26 Feb 2024
Net transactions value
-$825,261
Form type
4
Filing time
28 Feb 2024, 21:33:56 UTC
Previous filing
24 Jan 2024
Next filing
01 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KRYS Common Stock Options Exercise $261,300 +5,000 +40% $52.26 17,556 26 Feb 2024 Direct F1
transaction KRYS Common Stock Sale $675,000 -5,000 -28% $135.00 12,556 26 Feb 2024 Direct F1, F2
transaction KRYS Common Stock Options Exercise $161,327 +3,087 +25% $52.26 15,643 26 Feb 2024 Direct F3
transaction KRYS Common Stock Sale $432,180 -3,087 -20% $140.00 12,556 26 Feb 2024 Direct F2, F3
transaction KRYS Common Stock Tax liability $240,681 -1,533 -12% $157.00 11,023 26 Feb 2024 Direct F4, F5
transaction KRYS Common Stock Options Exercise $99,973 +1,913 +17% $52.26 12,936 27 Feb 2024 Direct F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KRYS Stock Option (Right to Buy) Options Exercise $0 -5,000 -50% $0.000000 5,000 26 Feb 2024 Common Stock 5,000 $52.26 Direct F1, F7
transaction KRYS Stock Option (Right to Buy) Options Exercise $0 -3,087 -62% $0.000000 1,913 26 Feb 2024 Common Stock 3,087 $52.26 Direct F3, F7
transaction KRYS Stock Option (Right to Buy) Options Exercise $0 -1,913 -100% $0.000000* 0 27 Feb 2024 Common Stock 1,913 $52.26 Direct F6, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $135.00 per share.
F2 The transaction was executed in multiple trades at the same sale price.
F3 The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 3,087 shares with a limit price of $140.00 per share.
F4 Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 4,900 shares of restricted stock on February 26, 2024.
F5 The closing price on February 26, 2024 of the Company's common stock on NASDAQ.
F6 The option exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and holding 1,913 shares with a prior closing price from $135.00 per share.
F7 50,000 options were granted that vest in four equal annual installments beginning on January 20, 2021.